Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Healthcare Biotechnology
Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Vaxil Bio Ltd > 20 Minute Video with CEO💉💚WORTH WATCHING
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(38)
•••
Comment by bligickaon Feb 18, 2021 6:51pm
104 Views
Post# 32605292

RE:RE:RE:20 Minute Video with CEO💉💚WORTH WATCHING

RE:RE:RE:20 Minute Video with CEO💉💚WORTH WATCHING AGREE 100% !!!

The way this all played out raises alot of questions ....can this be traced back to the Ceo ???

Why didn't the stock get halted first thing in the morning if news was ready to diseminate anyways ??? 

Why can't they look at the trades first thing in the morning and see who exactly was selling those 300k shares that decimated the share price in seconds ??? I know for a fact they can trace those trades !!!

Suspicious trading for sure .....and then the Venture ended up calling the company and poof they had a release ready just like that .....hhhhmmmm ???








stockmonster6 wrote: The market doesn't respond by a 60% down turn, without a new release.
IIROC should investigate why and how this happened.

Yes, it was bad news. But it tanked before the NR was released.



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities